| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eda1ad3d44d6174eaff8b8c172066d44 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2077
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61J3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-375 |
| filingDate |
2006-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2010-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a48c5aa7823d3aac78b509498fcac8e6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b63e2498664a5a972277f0d943ce30d4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a80af7291ab0cc61c6752f53d2e2698f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d600b8c86fbe72c69c70f544780fc2c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2f31939eb61dfc85b0dff2a2bbd0bd7 |
| publicationDate |
2010-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2385712-C2 |
| titleOfInvention |
Controlled-release formulation |
| abstract |
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: oral controlled-release dosage form includes granules of therapeutically effective amount of pharmacologically high water-soluble active substance, and at least one nonpolymeric release inhibitor. Said granules are combined at least with one pH-independent nonswelling release inhibitor representing a polymer. Nonpolymeric release inhibitor represents glyceryl behenate. Polymeric pH-independent release inhibitor preferentially represents mixed polyvinyl acetate and polyvinyl pyrrolidone (Collidone SR). The active substance preferentially represents vitamin C. ^ EFFECT: dosage form provides controlled release of an active component with the reduced initial "explosive" release. ^ 34 cl, 4 dwg, 19 tbl, 10 ex |
| priorityDate |
2005-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |